ADAP and SKAP 55 deficiency suppresses PD ‐1 expression in CD 8 ⁺ cytotoxic T lymphocytes for enhanced anti‐tumor immunotherapy

Abstract

PD-1 negatively regulates CD8+ cytotoxic T lymphocytes (CTL) cytotoxicity and anti-tumor immunity. However, it is not fully understood how PD-1 expression on CD8+ CTL is regulated during anti-tumor immunotherapy. In this study, we have identified that the ADAP-SKAP55 signaling module reduced CD8+ CTL cytotoxicity and enhanced PD-1 expression in a Fyn-, Ca2+-, and NFATc1-dependent manner. In DC vaccine-based tumor prevention and therapeutic models, knockout of SKAP55 or ADAP showed a heightened protection from tumor formation or metastases in mice and reduced PD-1 expression in CD8+ effector cells. Interestingly, CTLA-4 levels and the percentages of tumor infiltrating CD4+Foxp3+ Tregs remained unchanged. Furthermore, adoptive transfer of SKAP55-deficient or ADAP-deficient CD8+ CTLs significantly blocked tumor growth and increased anti-tumor immunity. Pretreatment of wild-type CD8+ CTLs with the NFATc1 inhibitor CsA could also downregulate PD-1 expression and enhance anti-tumor therapeutic efficacy. Together, we propose that targeting the unrecognized ADAP-SKAP55-NFATc1-PD-1 pathway might increase efficacy of anti-tumor immunotherapy.

SKAP2 Promotes Podosome Formation to Facilitate Tumor-Associated Macrophage Infiltration and Metastatic Progression

“…þ CTLs, which increases antitumor immunity (35). In addition, expression of PD-1 ligands PD-L1/B7-H1 and B7-H4 in macrophages inhibits antitumor immune responses (36).…”

Expression deregulation of mir31 and CXCL12 in two types of oral precancers and cancer: importance in progression of precancer and cancer

“…FYB (also known as ADAP and SLAP-130 ) participates in T-cell receptor mediated actin cytoskeletal rearrangement with activation of integrins function, T cell migration and production of cytokines323334. Knockout of FYB gives protection against tumor formation and metastasis in mice35. So, expression deregulation of FYB might impair the immune system of cancer cells.…”

Treg depletion potentiates checkpoint inhibition in claudin-low breast cancer

“…All human tumor and normal tissue samples were obtained from fresh-frozen invasive breast carcinomas that were profiled, as described previously, using oligo immune checkpoint inhibition received i.p. injection of 100 μg anti-CTLA-4 (9D9), 200 μg anti-PD-1 (J43), or isotype antibody on day -1 PTI and then every other day throughout the experiment (40,41). Mice undergoing Treg depletion (DEREG mice) received i.p.…”